Global Annualized Recurrence Rates and Dynamic Risk Profiles in Head and Neck Cancer
International Journal of Cancer · 01.01.2027 · 160 (1) · 44-56
DOI: 10.1002/ijc.70675 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Cancer, online erschienen am 26.07.2026. Verfasst von Yiqiao Fang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thyroid Surgery, Department of General Surgery, Laboratory of Thyroid and Parathyroid Diseases, Frontiers Science Center for Disease-Rela…. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: National Natural Science Foundation of China, The Science and Technology Department of Sichuan Province.
Abstract (Originalsprache)
Recurrence limits survival in head and neck cancer (HNC), yet its annualized rate remains poorly defined due to heterogeneous follow‐up durations across studies. In this systematic review and meta‐analysis, we searched four databases from inception to May 1, 2025, and included 1060 studies comprising 336,615 patients and 1.40 million person‐years of follow‐up. Using person‐time analysis, we estimated a global recurrence rate of 6.57 per 100 person‐years (95% CI, 6.28–6.87). Recurrence rates varied substantially across settings, with higher rates observed in lower‐middle‐income countries (10.16 per 100 person‐years) and in hypopharyngeal cancers (14.11 per 100 person‐years). Median follow‐up duration explained the largest share of between‐study heterogeneity ( R 2 = 37.12%), and studies with shorter reported follow‐up tended to show higher annualized recurrence rates. Substantial differences in recurrence rates were noted when stratified by clinical and biological factors. Notably, the prognostic impact of patient age and tumor stage was time‐dependent, being most pronounced in the early post‐treatment period and attenuating over time. Patients with recurrent disease faced a high mortality risk, with a pooled case fatality rate of 55.80% (95% CI, 51.20–60.30). These findings quantify a high global recurrence rate of HNC with pronounced time dependence, informing risk‐adapted surveillance strategies and early, histology‐specific prevention to reduce recurrence‐related mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Thyroid Surgery, Department of General Surgery, Laboratory of Thyroid and Parathyroid Diseases, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengd…
- Department of Medical Ultrasound, West China Hospital, Sichuan University, Chengdu, China.
- Department of Respiratory and Critical Care Medicine, Frontiers Science Center for Disease-Related Molecular Network, Center of Precision Medicine, Precision Medicine Key Laboratory of Sichuan Province, West China Hospi…
- Department of Obstetrics and Gynecology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Förderung
- National Natural Science Foundation of China
- The Science and Technology Department of Sichuan Province
Zitieren
APA
Fang, Y., Yi, C., Sun, R., Shen, B., Yao, M., Yang, Y., Ni, Y., Liu, Y., Li, Z., & Liu, J. (2027). Global Annualized Recurrence Rates and Dynamic Risk Profiles in Head and Neck Cancer. International Journal of Cancer, 160(1), 44-56. https://doi.org/10.1002/ijc.70675
Vancouver
Fang Y, Yi C, Sun R, Shen B, Yao M, Yang Y, et al. Global Annualized Recurrence Rates and Dynamic Risk Profiles in Head and Neck Cancer. International Journal of Cancer. 2027;160(1):44-56. doi:10.1002/ijc.70675
BibTeX
@article{Fang2027,
author = {Fang, Yiqiao and Yi, Cheng and Sun, Ruonan and Shen, Bingbing and Yao, Menglin and Yang, Ying and Ni, Yinyun and Liu, Yang and Li, Zhihui and Liu, Jiaye},
title = {Global Annualized Recurrence Rates and Dynamic Risk Profiles in Head and Neck Cancer},
journal = {International Journal of Cancer},
year = {2027},
volume = {160},
number = {1},
pages = {44--56},
doi = {10.1002/ijc.70675}
}
EUVIMED